載入...
Lipoprotein(a) and PCSK9 inhibition: clinical evidence
Compelling evidence has emerged from epidemiological and Mendelian randomization analyses relative to the causality of lipoprotein(a) [Lp(a)] in atherosclerotic cardiovascular diseases (ASCVD), being elevated Lp(a) a strong risk factor regardless of the reduction of LDL-C achieved by statins. So far...
Na minha lista:
| 發表在: | Eur Heart J Suppl |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7673619/ https://ncbi.nlm.nih.gov/pubmed/33239979 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/suaa135 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|